文献速递眼底病与葡萄膜炎

哺乳动物雷帕霉素靶蛋白抑制作为预防增生性玻璃体视网膜病变的治疗靶点

Mammalian Target Rapamycin Inhibition as a Therapeutic Target for Prevention of Proliferative Vitreoretinopathy.
PubMed 文献 · JAMA Ophthalmol · 2025-01-01

这项回顾性队列研究汇总2003年1月至2025年1月15个国家的去标识电子健康记录数据,比较初次视网膜脱离修复时接受全身哺乳动物雷帕霉素靶蛋白抑制剂(MTI)治疗的681例患者与未暴露于全身mTOR抑制的47626例对照。倾向评分匹配后随访1年,MTI组发生后续视网膜脱离、需玻璃体切割术和复杂视网膜脱离修复的风险均降低;与匹配的全身甲氨蝶呤治疗队列在6个月和1年时各项结局无差异。作者认为未来需研究MTI在此场景中的安全性和有效性。

要点

  • 初次视网膜脱离修复时联用全身MTI与1年后续视网膜脱离风险降低相关(RR 0.58)。
  • 联用全身MTI与1年需玻璃体切割术风险降低相关(RR 0.57)。
  • 联用全身MTI与1年需复杂视网膜脱离修复风险降低相关(RR 0.60)。

核心结论

  • 初次视网膜脱离修复时联用全身MTI治疗的患者,相比未暴露于全身MTI的匹配患者,发生后续PVR相关视网膜脱离的可能性更低。
  • 未来需开展研究探讨MTI在此潜在PVR预防场景中的安全性和有效性。

研究设计与样本

  • 回顾性队列研究,汇总2003年1月至2025年1月来自15个国家的去标识电子健康记录数据。
  • 纳入681例在初次视网膜脱离修复前至少3个月及后1年接受全身MTI治疗的患者,与47626例从未暴露于全身mTOR抑制的对照组比较。
  • 倾向评分匹配后,分析每组681例患者初次视网膜脱离手术后1年的结局;另将MTI组与联用全身甲氨蝶呤的匹配队列在6个月和1年时比较相同指标。

主要发现

  • 倾向评分匹配前,MTI队列681例,平均(SD)年龄66.5(15.4)岁,女性319例(46.8%)、男性319例(46.8%);对照组47626例,平均(SD)年龄64.5(17.6)岁,女性16140例(33.9%)、男性27858例(58.5%)。
  • 1年时,与未暴露于全身MTI的匹配患者相比,联用全身MTI与发生后续视网膜脱离风险降低相关(RR 0.58;95%CI 0.36-0.94;P=0.03)。
  • 1年时,与未暴露于全身MTI的匹配患者相比,联用全身MTI与需后续玻璃体切割术风险降低相关(RR 0.57;95%CI 0.40-0.82;P<0.001)。
  • 1年时,与未暴露于全身MTI的匹配患者相比,联用全身MTI与需复杂视网膜脱离修复风险降低相关(RR 0.60;95%CI 0.40-0.91;P=0.01)。
  • 在6个月和1年时,联用全身MTI的患者与联用全身甲氨蝶呤的匹配队列相比,后续视网膜脱离发生、需玻璃体切割术或复杂视网膜脱离修复均无差异。

关键数值与推荐

  • 暴露定义:通过RxNorm代码分层为使用或不使用全身mTOR治疗。
  • 主要结局指标:发生PVR相关视网膜脱离及需后续眼部干预(包括玻璃体切割术和复杂视网膜脱离修复)的相对风险,随访6个月和1年。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The use of systemic mammalian target of rapamycin (mTOR) inhibitor (MTI) therapy may confer benefits against the development of proliferative vitreoretinopathy (PVR). OBJECTIVE: To examine the use of systemic MTI therapy for the prevention of PVR among patients who underwent initial retinal detachment (RD) repair. DESIGN, SETTING, AND PARTICIPANTS: This was a retrospective cohort study aggregating deidentified electronic health record data from January 2003 to January 2025, from 15 countries. The study included 681 patients who underwent primary RD repair while receiving systemic MTI therapy at least 3 months before and 1 year after initial RD repair. This cohort was compared with a control group of 47 626 patients never exposed to systemic mTOR inhibition. After propensity score matching, outcomes from 681 patients in each cohort were analyzed after 1 year following their initial RD surgery. EXPOSURES: Patients were stratified by use of systemic mTOR therapy or not using RxNorm code. MAIN OUTCOME AND MEASURES: Relative risk (RR) of developing a PVR-related RD and requiring a subsequent ocular intervention including pars plana vitrectomy (PPV), and complex RD repair within 6 months and 1 year of follow-up. Patients who underwent initial RD repair while receiving systemic MTI therapy were separately compared with a matched cohort of patients with concomitant use of systemic methotrexate (MTX) for the same measures at 6 months and 1 year. RESULTS: A total of 681 and 47 626 patients who underwent initial RD repair with concomitant use of an MTI or not, respectively, were identified prior to PSM. The mean (SD) age in the MTI cohort was 66.5 (15.4) years; 319 (46.8%) were female and 319 (46.8%) were male. In the control cohort, the mean (SD) age was 64.5 (17.6) years; 16 140 (33.9%) were female and 27 858 (58.5%) were male. At 1 year, concomitant use of systemic MTI therapy was associated with a decreased risk of developing a subsequent RD (RR, 0.58; 95% CI, 0.36-0.94; P = .03) compared with matched patients who underwent initial RD repair without exposure to systemic MTI therapy. Moreover, concomitant use of systemic MTI therapy was associated with a decreased risk of requiring subsequent PPV (RR, 0.57; 95% CI, 0.40-0.82; P < .001) and complex RD repair (RR, 0.60; 95% CI, 0.40-0.91; P = .01) when compared with matched patients who underwent initial RD repair without exposure to systemic MTI therapy at 1 year. There was no difference in the development of subsequent RD and need for PPV or complex RD repair when comparing patients who underwent initial RD repair with concomitant systemic MTI therapy to a matched cohort of patients with concomitant use of systemic MTX therapy at 6 months and 1 year. CONCLUSION AND RELEVANCE: Patients who underwent initial RD repair and were concomitantly being treated with systemic MTI therapy were less likely to develop a subsequent PVR-related RD compared with matched patients not exposed to systemic MTI therapy. Future studies are needed to investigate MTI therapy safety and efficacy profile in this setting of potential PVR prevention.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Alsoudi AF, Loya A, Wai K, et al. Mammalian Target Rapamycin Inhibition as a Therapeutic Target for Prevention of Proliferative Vitreoretinopathy. JAMA Ophthalmol. 2025. PMID: 40773191. doi:10.1001/jamaophthalmol.2025.2497

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。